Pharmosa Biopharm (ROCO:6875) Change In Payables And Accrued Expense : NT$0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Pharmosa Biopharm Change In Payables And Accrued Expense?

Pharmosa Biopharm's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was NT$0.0 Mil. It means Pharmosa Biopharm's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

Pharmosa Biopharm's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was NT$0.0 Mil. It means Pharmosa Biopharm's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Pharmosa Biopharm Change In Payables And Accrued Expense Historical Data

The historical data trend for Pharmosa Biopharm's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmosa Biopharm Change In Payables And Accrued Expense Chart

Pharmosa Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Pharmosa Biopharm Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial												-	-	-	-	-

Pharmosa Biopharm Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

Pharmosa Biopharm Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharmosa Biopharm's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmosa Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmosa Biopharm Inc (ROCO:6875) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Sec. 7, Zhongxiao E. Road, 11F / 11F-1, Nangang District, Taipei, TWN

Website

https://www.pharmosa.com.tw

Pharmosa Biopharm Inc is a world-class biotechnology company focusing on developing a new drug by exploiting proprietary formulation and manufacturing technology. Geographically, the company generates almost all of its revenue from the USA, and a small portion from Taiwan.

Pharmosa Biopharm Headlines

No Headlines